Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.63 |
| ▸ | NPY1R | P25929 | 9/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.63 |
| ▸ | NPY2R | P49146 | 5/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.55 |
| ▸ | CCKAR | P32238 | 2/20 | 0.53 |
| ▸ | CCKBR | P32239 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30820031 | 0.92 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL6469201 | 0.91 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30198871 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL31232460 | 0.90 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL31571458 | 0.90 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30483971 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29637822 | 0.89 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30603887 | 0.89 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL31265336 | 0.89 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29462566 | 0.88 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | CUTA, GLA, LIPA | NPY4R 1131/4885NPY1R 474/4885NPY5R 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.